Evelo Biosciences Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Out of Business

  • Employees
  • 66

Employees

  • Latest Deal Type
  • Liquidation

Evelo Biosciences General Information

Description

Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new class of orally delivered investigational medicines that are intended to act on cells in the small intestine to produce therapeutic effects throughout the body. Its lead product candidate under development is EDP1815, which is for the treatment of inflammatory diseases and the hyperinflammatory response associated with COVID-19. Other products in the pipeline include EDP1867 and EDP2939 for the treatment of inflammatory disease and EDP1908 for the treatment of cancer.

Contact Information

Formerly Known As
Evelo Therapeutics, VL28
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 620 Memorial Drive
  • Cambridge, MA 02139
  • United States
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 620 Memorial Drive
  • Cambridge, MA 02139
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Evelo Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Bankruptcy: Liquidation 20-Nov-2023 Completed Bankruptcy: Liquidation
9. Debt Refinancing 01-Oct-2023 Completed Generating Revenue
8. PIPE 11-Jul-2023 Completed Generating Revenue
7. PIPE 02-Feb-2021 Completed Generating Revenue
6. Secondary Transaction - Open Market Completed Generating Revenue
5. IPO 08-May-2018 Completed Generating Revenue
4. Later Stage VC (Series C) 23-Mar-2018 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 17-Jan-2017 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Jun-2016 $16.6M $30.7M Completed Startup
1. Early Stage VC (Series A) 04-Nov-2015 $14M $14M Completed Startup
To view Evelo Biosciences’s complete valuation and funding history, request access »

Evelo Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A3
Series A2
Series A1 10,164,552 $0.001000 8% $0.6 $0.6 1x $0.6 8.18%
Series A 13,470,279 $0.001000 8% $0.6 $0.6 1x $0.6 10.84%
To view Evelo Biosciences’s complete cap table history, request access »

Evelo Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Evelo Biosciences Inc is a United States-based biotechnology company. It is engaged in discovering and developing a new
Biotechnology
Cambridge, MA
66 As of 2022

Cambridge, MA
 

Aberdeen, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evelo Biosciences Competitors (123)

One of Evelo Biosciences’s 123 competitors is Seres Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Seres Therapeutics Formerly VC-backed Cambridge, MA
NovaBiotics Venture Capital-Backed Aberdeen, United Kingdom
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
Innovimmune Biotherapeutics Accelerator/Incubator Backed New York, NY
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 123 competitors. Get the full list »

Evelo Biosciences Patents

Evelo Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250127823-A1 Compositions and methods of affecting cytokine levels using prevotella histicola Pending 07-Feb-2022
EP-4404921-A1 Solid dosage forms containing bacteria and microbial extracellular vesicles Pending 24-Sep-2021
US-20250114411-A1 Solid dosage forms containing bacteria and microbial extracellular vesicles Pending 24-Sep-2021
EP-4319723-A1 Pharmaceutical composition containing bacteria Inactive 08-Apr-2021
US-20250073285-A1 Pharmaceutical composition containing bacteria Pending 08-Apr-2021 A61K35/747
To view Evelo Biosciences’s complete patent history, request access »

Evelo Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evelo Biosciences Acquisitions (1)

Evelo Biosciences’s most recent deal was a Merger/Acquisition with Epiva Biosciences. The deal was made on 12-Jul-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Epiva Biosciences 12-Jul-2016 Merger/Acquisition Biotechnology
To view Evelo Biosciences’s complete acquisitions history, request access »

Evelo Biosciences ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

35.17 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,912

Rank

Percentile

Pharmaceuticals

Industry

of 965

Rank

Percentile

Biotechnology

Subindustry

of 443

Rank

Percentile

To view Evelo Biosciences’s complete esg history, request access »

Evelo Biosciences FAQs

  • When was Evelo Biosciences founded?

    Evelo Biosciences was founded in 2014.

  • Where is Evelo Biosciences headquartered?

    Evelo Biosciences is headquartered in Cambridge, MA.

  • What is the size of Evelo Biosciences?

    Evelo Biosciences has 66 total employees.

  • What industry is Evelo Biosciences in?

    Evelo Biosciences’s primary industry is Biotechnology.

  • Is Evelo Biosciences a private or public company?

    Evelo Biosciences is a Private company.

  • What is Evelo Biosciences’s current revenue?

    The current revenue for Evelo Biosciences is .

  • How much funding has Evelo Biosciences raised over time?

    Evelo Biosciences has raised $306M.

  • Who are Evelo Biosciences’s competitors?

    Seres Therapeutics, NovaBiotics, Light Chain Bioscience, Innovimmune Biotherapeutics, and Inovio Pharmaceuticals are some of the 123 competitors of Evelo Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »